Validation pour Ingenuity259

vers la météo de la validation par utilisateur

Ingenuity259

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 12 - PMID ?

In liver from SP , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of SP NODE mRNA that involves oral administration of NODE ( with a treatment period of 6 weeks ) .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 1

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 2

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 3

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 4

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 5

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 6

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 7

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 8

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 9

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 10

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 11

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 12

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 13

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 14

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 15

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 16

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 17

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 18

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 19

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 20

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 21

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 22

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 23

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 24

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 25

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 26

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 27

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 28

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 29

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 30

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 31

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 32

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 33

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 34

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 35

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 36

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 37

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 38

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 39

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 40

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 41

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 42

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 43

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 44

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 45

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 46

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 47

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 48

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 49

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 50

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 51

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 52

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 53

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 54

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 55

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 56

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 57

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 58

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 59

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 60

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 61

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 62

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 63

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 64

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 65

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 66

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 67

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 68

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 69

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 70

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 71

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 72

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 73

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 74

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 75

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 76

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 77

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 78

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 79

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 80

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 81

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 82

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 83

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 84

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 85

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 86

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 87

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 88

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 89

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 90

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 91

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 92

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 93

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 94

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 95

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 96

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 97

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 98

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 99

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 100

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 101

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 102

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 103

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 104

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 105

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 106

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 107

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 108

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 109

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 110

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 111

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 112

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 113

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 114

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 115

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 116

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 117

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 118

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 119

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 120

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 121

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 122

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 123

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 124

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 125

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 126

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 127

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 128

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 129

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 130

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 131

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 132

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 133

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 134

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 135

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 136

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 137

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 138

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 139

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 140

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 141

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 142

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 143

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 144

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 145

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 146

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 147

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 148

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 149

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 150

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 151

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 152

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 153

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 154

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 155

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 156

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 157

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 158

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 159

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 160

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 161

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 162

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 163

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 164

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 165

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 166

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 167

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 168

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 169

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 170

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 171

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 172

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 173

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 174

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 175

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 176

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 177

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 178

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 179

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 180

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 181

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 182

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 183

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 184

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 185

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 186

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 187

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 188

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 189

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 190

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 191

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 192

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 193

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 194

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 195

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 196

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 197

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 198

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 199

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 200

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 201

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 202

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 203

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 204

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 205

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 206

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 207

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 208

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 209

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 210

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 211

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 212

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 213

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 214

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 215

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 216

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 217

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 218

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 219

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 220

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 221

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 222

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 223

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 224

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 225

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 226

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 227

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 228

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 229

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 230

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 231

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 232

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 233

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 234

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 235

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 236

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 237

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 238

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 239

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 240

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 241

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 242

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 243

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 244

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 245

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 246

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 247

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 248

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 249

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 250

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 251

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 252

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 253

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 254

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 255

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 256

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 257

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 258

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 259

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 260

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 261

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 262

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 263

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 264

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 265

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 266

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 267

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 268

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 269

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 270

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 271

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 272

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 273

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 274

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 275

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 276

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 277

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 278

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 279

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 280

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 281

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 282

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 283

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 284

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 285

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 286

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 287

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 288

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 289

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 290

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 291

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 292

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 293

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 294

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 295

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 296

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 297

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 298

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 299

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 300

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 301

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 302

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 303

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 304

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 305

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 306

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 307

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 308

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 309

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 310

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 311

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 312

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 313

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 314

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 315

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 316

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 317

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 318

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 319

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 320

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 321

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 322

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 323

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 324

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 325

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 326

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 327

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 328

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 329

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 330

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 331

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 332

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 333

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 334

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 335

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 336

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 337

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 338

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 339

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 340

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 341

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 342

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 343

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 344

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 345

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 346

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 347

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 348

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 349

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 350

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 351

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 352

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 353

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 354

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 355

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 356

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 357

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 358

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 359

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 360

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 361

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 362

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 363

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 364

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 365

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 366

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 367

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 368

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 369

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 370

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 371

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 372

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 373

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 374

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 375

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 376

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 377

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 378

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 379

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 380

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 381

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 382

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 383

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 384

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 385

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 386

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 387

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 388

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 389

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 390

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 391

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 392

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 393

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 394

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 395

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 396

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 397

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 398

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 399

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 400

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 401

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 402

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 403

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 404

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 405

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 406

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 407

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 408

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 409

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 410

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 411

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 412

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 413

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 414

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 415

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 416

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 417

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 418

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 419

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 420

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 421

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 422

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 423

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 424

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 425

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 426

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 427

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 428

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 429

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 430

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 431

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 432

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 433

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 434

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 435

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 436

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 437

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 438

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 439

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 440

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 441

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 442

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 443

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 444

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 445

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 446

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 447

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 448

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 449

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 450

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 451

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 452

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 453

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 454

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 455

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 456

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 457

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 458

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 459

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 460

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 461

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 462

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 463

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 464

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 465

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 466

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 467

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 468

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 469

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 470

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 471

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 472

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 473

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 474

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 475

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 476

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 477

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 478

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 479

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 480

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 481

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 482

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 483

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 484

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 485

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 486

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 487

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 488

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 489

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 490

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 491

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 492

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 493

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 494

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 495

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 496

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 497

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 498

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 499

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 500

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 501

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 502

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 503

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 504

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 505

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 506

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 507

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 508

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 509

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 510

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 511

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 512

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 513

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 514

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 515

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 516

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 517

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 518

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 519

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 520

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 521

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 522

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 523

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 524

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 525

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 526

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 527

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 528

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 529

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 530

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 531

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 532

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 533

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 534

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 535

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 536

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 537

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 538

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 539

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 540

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 541

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 542

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 543

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 544

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 545

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 546

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 547

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 548

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 549

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 550

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 551

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 552

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 553

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 554

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 555

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 556

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 557

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 558

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 559

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 560

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 561

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 562

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 563

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 564

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 565

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 566

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 567

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 568

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 569

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 570

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 571

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 572

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 573

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 574

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 575

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 576

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 577

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 578

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 579

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 580

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 581

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 582

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 583

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 584

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 585

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 586

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 587

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 588

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 589

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 590

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 591

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 592

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 593

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 594

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 595

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 596

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 597

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 598

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 599

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 600

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 601

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 602

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 603

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 604

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 605

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 606

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 607

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 608

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 609

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 610

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 611

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 612

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 613

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 614

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 615

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 616

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 617

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 618

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 619

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 620

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 621

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 622

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 623

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 624

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 625

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 626

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 627

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 628

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 629

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 630

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 631

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 632

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 633

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 634

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 635

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 636

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 637

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 638

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 639

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 640

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 641

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 642

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 643

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 644

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 645

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 646

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 647

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 648

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 649

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 650

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 651

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
                                                                                                                                                                             |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 652

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 653

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 654

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 655

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 656

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 657

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 658

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 659

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

Analyse 660

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 661

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 662

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 663

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 664

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 665

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 666

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 667

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 668

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 669

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 670

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 671

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 672

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 673

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 674

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 675

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 676

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 677

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 678

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 679

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 680

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 681

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 682

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 683

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 684

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 685

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 686

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 687

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 688

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 689

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 690

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 691

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 692

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 693

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 694

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 695

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

Analyse 696

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)